Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies.
<h4>Objective</h4>The optimal sequencing of targeted therapies for metastatic renal cell carcinoma (mRCC) is unknown. Observational studies with a variety of designs have reported differing results. The objective of this study is to systematically summarize and interpret the published re...
Saved in:
| Main Authors: | Daniel Y Heng, James Signorovitch, Elyse Swallow, Nanxin Li, Yichen Zhong, Paige Qin, Daisy Y Zhuo, Xufang Wang, Jinhee Park, Sotirios Stergiopoulos, Christian Kollmannsberger |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2014-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0114264 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Impact of first-line tyrosine kinase inhibitor selection on survival outcomes with second-line nivolumab in metastatic renal cell carcinoma
by: Omer Faruk Kuzu, et al.
Published: (2025-07-01) -
Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma
by: Maryam Soleimani, et al.
Published: (2024-04-01) -
Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma
by: Maryam Soleimani, et al.
Published: (2025-04-01) -
Efficacy and safety of FOLFIRI/aflibercept in second‐line treatment of metastatic colorectal cancer in a real‐world population: Prognostic and predictive markers
by: Ana Fernández Montes, et al.
Published: (2019-03-01) -
Indirect treatment comparisons including network meta-analysis: Lenvatinib plus everolimus for the second-line treatment of advanced/metastatic renal cell carcinoma.
by: Gabriel Tremblay, et al.
Published: (2019-01-01)